pSivida signs $33.7m MOU to fund eye disease treatment

Perth-based biotechnology comapny pSivida Ltd has signed a $33.7 million agreement with an unnamed investment fund to finance development of the company's diabetic macular edema treatment.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

BNiQ Disclaimer